All In Biotech

Drug Trial Radar · NCT00517153

Miglustat in Niemann-Pick Type C Disease

A Phase II Randomized Controlled Study of Miglustat in Adult and Juvenile Patients With Niemann-Pick Type C Disease

Last checked: Nov 20, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Jan 2002

Primary completion

Sep 2006

Study completion Jan 2008

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 16, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II randomized controlled study of miglustat in adult and juvenile patients with Niemann-Pick Type C disease. Up to 42 patients will be randomised in a 2:1 ratio to either treatment with miglustat or to a non-treatment group. Both groups will follow an identical visit schedule.

Conditions

  • Niemann-Pick Type C Disease

Interventions

  • miglustatDrug

    Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoints will be two parameters - Horizontal Saccadic α and Horizontal Saccadic β - which are estimated for each patient from their saccadic eye movement dataTime frame: Baseline to Month 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.